Stereotactic Body Radiotherapy for Spinal Oligometastases: a Survey on Patterns of Practice on Behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO)

Overview

Journal Clin Exp Metastasis

Specialty Oncology

Date 2024 Aug 1

PMID 39088084

Authors

Francesco Cuccia

Ciro Franzese

Serena Badellino

Paolo Borghetti

Manuela Federico

Giulia Marvaso

Giampaolo Montesi

Antonio Pontoriero

Giuseppe Ferrera

Filippo Alongi

Marta Scorsetti

Affiliations

Soon will be listed here.

Abstract

Background: The Study Group for the Biology and Treatment of the OligoMetastatic Disease on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) has conducted a national survey with the aim to depict the current patterns of practice of stereotactic body radiotherapy (SBRT) for spinal oligometastases.

Methods: The Surveymonkey platform was used to send a 28-items questionnaire focused on demographic, clinical and technical aspects related to SBRT for spinal oligometastases. All the AIRO members were invited to fill the questionnaire. Data were then centralized to a single center for analysis and interpretation.

Results: 53 radiation oncologists from 47 centers fulfilled the survey. A complete agreement was observed in proposing SBRT for spinal oligometastases, with the majority considering up to 3 concurrent spine oligometastases feasible for SBRT (73.5%), regardless of spine site (70%), vertebral segment (85%) and morphological features of the lesion (71.7%). Regarding dose prescription, fractionated regimens resulted as the preferred option, either in 3 (58.4%) or five sessions (34%), with a substantial agreement in applying a PTV-margin larger than 1 mm (almost 90% of participants), and ideally using both MRI and PET imaging to improve target volume and organs-at-risk delineation (67.9%).

Conclusions: This national italian survey illustrates the patterns of practice and the main issues for the indication of SBRT for spinal oligometastases. A substantial agreement in the numerical cut-off and vertebral segment involved for SBRT indication was reported, with a slight heterogeneity in terms of dose prescription and fractionation schemes.

References

Ryan C, Stoltzfus K, Horn S, Chen H, Louie A, Lehrer E . Epidemiology of bone metastases. Bone. 2020; 158:115783. DOI: 10.1016/j.bone.2020.115783. View

Guckenberger M, Lievens Y, Bouma A, Collette L, Dekker A, deSouza N . Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1):e18-e28. DOI: 10.1016/S1470-2045(19)30718-1. View

Chalkidou A, Macmillan T, Grzeda M, Peacock J, Summers J, Eddy S . Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study. Lancet Oncol. 2021; 22(1):98-106. DOI: 10.1016/S1470-2045(20)30537-4. View

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C . Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol. 2020; 38(25):2830-2838. PMC: 7460150. DOI: 10.1200/JCO.20.00818. View

Tsai C, Yang J, Shaverdian N, Patel J, Shepherd A, Eng J . Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label,.... Lancet. 2023; 403(10422):171-182. PMC: 10880046. DOI: 10.1016/S0140-6736(23)01857-3. View

Francolini G, Allegra A, Detti B, Di Cataldo V, Caini S, Bruni A . Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023; 41(36):5561-5568. DOI: 10.1200/JCO.23.00985. View

Ouyang W, Yu J, Nuerjiang S, Li Z, Wang D, Wang X . Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer. Cancer Med. 2019; 8(10):4605-4614. PMC: 6712475. DOI: 10.1002/cam4.2366. View

Guckenberger M, Mantel F, Sweeney R, Hawkins M, Belderbos J, Ahmed M . Long-Term Results of Dose-Intensified Fractionated Stereotactic Body Radiation Therapy (SBRT) for Painful Spinal Metastases. Int J Radiat Oncol Biol Phys. 2021; 110(2):348-357. DOI: 10.1016/j.ijrobp.2020.12.045. View

Sprave T, Verma V, Forster R, Schlampp I, Bruckner T, Bostel T . Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy. Radiother Oncol. 2018; 128(2):274-282. DOI: 10.1016/j.radonc.2018.04.030. View

10.

Sahgal A, Myrehaug S, Siva S, Masucci G, Maralani P, Brundage M . Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2021; 22(7):1023-1033. DOI: 10.1016/S1470-2045(21)00196-0. View

11.

Diamond I, Grant R, Feldman B, Pencharz P, Ling S, Moore A . Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. J Clin Epidemiol. 2014; 67(4):401-9. DOI: 10.1016/j.jclinepi.2013.12.002. View

12.

Guckenberger M, Dahele M, Ong W, Sahgal A . Stereotactic Body Radiation Therapy for Spinal Metastases: Benefits and Limitations. Semin Radiat Oncol. 2023; 33(2):159-171. DOI: 10.1016/j.semradonc.2022.11.006. View

13.

Harrow S, Palma D, Olson R, Gaede S, Louie A, Haasbeek C . Stereotactic Radiation for the Comprehensive Treatment of Oligometastases (SABR-COMET): Extended Long-Term Outcomes. Int J Radiat Oncol Biol Phys. 2022; 114(4):611-616. DOI: 10.1016/j.ijrobp.2022.05.004. View

14.

Cuccia F, Pastorello E, Franzese C, Belgioia L, Bignardi M, Federico M . Stereotactic Body Radiotherapy for Spine Oligometastases: A Multicentre Retrospective Study From the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Clin Oncol (R Coll Radiol). 2023; 35(12):794-800. DOI: 10.1016/j.clon.2023.09.001. View

15.

Cox B, Spratt D, Lovelock M, Bilsky M, Lis E, Ryu S . International Spine Radiosurgery Consortium consensus guidelines for target volume definition in spinal stereotactic radiosurgery. Int J Radiat Oncol Biol Phys. 2012; 83(5):e597-605. DOI: 10.1016/j.ijrobp.2012.03.009. View

16.

Christ S, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P . Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E-RADIatE OligoCare study. Radiother Oncol. 2024; 195:110235. DOI: 10.1016/j.radonc.2024.110235. View

17.

Zeng K, Abugarib A, Soliman H, Myrehaug S, Husain Z, Detsky J . Dose-Escalated 2-Fraction Spine Stereotactic Body Radiation Therapy: 28 Gy Versus 24 Gy in 2 Daily Fractions. Int J Radiat Oncol Biol Phys. 2022; 115(3):686-695. DOI: 10.1016/j.ijrobp.2022.09.076. View

18.

Waltenberger M, Vogel M, Bernhardt D, Munch S, Dobiasch S, Redmond K . Radiotherapy concepts for spinal metastases-results from an online survey among radiation oncologists of the German Society for Radiation Oncology. Strahlenther Onkol. 2023; 200(2):159-174. PMC: 10805849. DOI: 10.1007/s00066-023-02082-w. View

19.

Pichon B, Rousseau C, Blanc-Lapierre A, Delpon G, Ferrer L, Libois V . Targeting Stereotactic Body Radiotherapy on Metabolic PET- and Immuno-PET-Positive Vertebral Metastases. Biomedicines. 2020; 8(12). PMC: 7760481. DOI: 10.3390/biomedicines8120548. View

20.

Di Franco R, Pezzulla D, Arcidiacono F, Pontoriero A, Cellini F, Belgioia L . Reirradiation on spine metastases: an Italian survey on behalf of palliative care and reirradiation study groups of Italian association of radiotherapy and clinical oncology (AIRO). Clin Transl Oncol. 2022; 25(2):408-416. DOI: 10.1007/s12094-022-02951-3. View